这是一篇来自已证抗体库的有关人类 GITR的综述,是根据15篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合GITR 抗体。
GITR 同义词: AITR; CD357; ENERGEN; GITR; GITR-D

BioLegend
小鼠 单克隆(108-17)
  • 流式细胞仪; 人类; 图 1c, s1a
BioLegend GITR抗体(Biolegend, 108-17)被用于被用于流式细胞仪在人类样本上 (图 1c, s1a). Oncoimmunology (2022) ncbi
小鼠 单克隆(108-17)
  • 流式细胞仪; 人类; 图 2a
BioLegend GITR抗体(BioLegend, 108-17)被用于被用于流式细胞仪在人类样本上 (图 2a). Front Immunol (2021) ncbi
小鼠 单克隆(621)
  • 流式细胞仪; 人类; 图 3a
  • 免疫细胞化学; 人类; 图 2c
BioLegend GITR抗体(Biolegend, 621)被用于被用于流式细胞仪在人类样本上 (图 3a) 和 被用于免疫细胞化学在人类样本上 (图 2c). Commun Biol (2021) ncbi
小鼠 单克隆(108-17)
  • 流式细胞仪; 人类; 图 7g
BioLegend GITR抗体(BioLegend, 371202)被用于被用于流式细胞仪在人类样本上 (图 7g). Cell (2018) ncbi
小鼠 单克隆(621)
  • mass cytometry; 人类; 图 2a
BioLegend GITR抗体(Biolegend, 621)被用于被用于mass cytometry在人类样本上 (图 2a). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆(621)
  • mass cytometry; 人类; 图 s8
BioLegend GITR抗体(BioLegend, 311602)被用于被用于mass cytometry在人类样本上 (图 s8). Nature (2017) ncbi
小鼠 单克隆(621)
  • 流式细胞仪; 人类; 图 st1
BioLegend GITR抗体(BioLegen, 311610)被用于被用于流式细胞仪在人类样本上 (图 st1). Exp Cell Res (2016) ncbi
赛默飞世尔
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类; 图 4b
赛默飞世尔 GITR抗体(eBioscience, eBioAITR)被用于被用于流式细胞仪在人类样本上 (图 4b). BMC Immunol (2020) ncbi
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类; 图 s3a
赛默飞世尔 GITR抗体(eBioscience, eBioAITR)被用于被用于流式细胞仪在人类样本上 (图 s3a). Cancer (2019) ncbi
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类; 图 1g
  • 流式细胞仪; 猕猴; 图 6g
赛默飞世尔 GITR抗体(eBioscience, 12-5875)被用于被用于流式细胞仪在人类样本上 (图 1g) 和 被用于流式细胞仪在猕猴样本上 (图 6g). PLoS Pathog (2016) ncbi
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类; 图 6a
赛默飞世尔 GITR抗体(eBioscience, eBioAITR)被用于被用于流式细胞仪在人类样本上 (图 6a). Oncotarget (2016) ncbi
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类; 图 3b
赛默飞世尔 GITR抗体(eBioscience, eBioAITR)被用于被用于流式细胞仪在人类样本上 (图 3b). Eur J Immunol (2016) ncbi
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类; 图 s2
赛默飞世尔 GITR抗体(eBioscience, 12-5875)被用于被用于流式细胞仪在人类样本上 (图 s2). Nat Commun (2015) ncbi
小鼠 单克隆(eBioAITR)
  • 流式细胞仪; 人类
赛默飞世尔 GITR抗体(eBioscience, eBioAITR)被用于被用于流式细胞仪在人类样本上. Clin Cancer Res (2014) ncbi
安迪生物R&D
小鼠 单克隆(110416)
  • mass cytometry; 人类; 图 s4a
安迪生物R&D GITR抗体(R&D, MAB689)被用于被用于mass cytometry在人类样本上 (图 s4a). Biomark Res (2022) ncbi
小鼠 单克隆(110416)
  • 抑制或激活实验; 人类; 图 4c
安迪生物R&D GITR抗体(R&D Systems, 110416)被用于被用于抑制或激活实验在人类样本上 (图 4c). Commun Biol (2021) ncbi
西格玛奥德里奇
小鼠 单克隆(2H4)
  • 免疫印迹; 人类; 2.5 ug/ml; 图 1c
西格玛奥德里奇 GITR抗体(SIGMA-ALDRICH, 2H4)被用于被用于免疫印迹在人类样本上浓度为2.5 ug/ml (图 1c). Commun Biol (2021) ncbi
文章列表
  1. Pan C, Wu Q, Wang S, Mei Z, Zhang L, Gao X, et al. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. Oncoimmunology. 2022;11:2073010 pubmed 出版商
  2. Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, et al. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022;10:13 pubmed 出版商
  3. Ming S, Yin H, Li X, Gong S, Zhang G, Wu Y. GITR Promotes the Polarization of TFH-Like Cells in Helicobacter pylori-Positive Gastritis. Front Immunol. 2021;12:736269 pubmed 出版商
  4. Chan M, Wu L, Yun Z, McKee T, Cabanero M, Zhao Y, et al. Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma. Commun Biol. 2021;4:914 pubmed 出版商
  5. Liu G, Yu Y, Feng F, Zhu P, Zhang H, Zhang D, et al. Human CD8+CD28- T suppressor cells expanded by common gamma chain (γc) cytokines retain steady allospecific suppressive capacity in vivo. BMC Immunol. 2020;21:23 pubmed 出版商
  6. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed 出版商
  7. Tavazoie M, Pollack I, Tanqueco R, Ostendorf B, Reis B, Gonsalves F, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018;172:825-840.e18 pubmed 出版商
  8. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed 出版商
  9. Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed 出版商
  10. Miles B, Miller S, Folkvord J, Levy D, Rakasz E, Skinner P, et al. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection. PLoS Pathog. 2016;12:e1005924 pubmed 出版商
  11. Komdeur F, Wouters M, Workel H, Tijans A, Terwindt A, Brunekreeft K, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130-75144 pubmed 出版商
  12. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  13. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed 出版商
  14. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed 出版商
  15. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, et al. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody. Clin Cancer Res. 2014;20:5052-63 pubmed 出版商